Income statement
USD
Annual
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Operating Income | -2M | -2M |
| EBITDA | -2M | -2M |
| Net Income | -2M | -2M |
| EPS (Diluted) | — | — |
Healthcare
Live Price
Offline$5.87
-2.65% today
Window Change
-13.64%
Window
Oct 8, 2025 → Jun 12, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 171 bars · Oct 8, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Turn Therapeutics Inc. (TTRX) is a Healthcare stock with a market cap of $110.00M and listed on NASDAQ. The stock last traded around $5.87 and down 13.6% across the available one-year price window (Oct 8, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -76.9%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -76.9%, free cash flow -85.9% with operating margin 0.0% and ROIC -94.4%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TTRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TTRX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TTRX Max Drawdown
-70.54%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TTRX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$2.3M
-29.6% YoY
Free Cash Flow
-$1.4M
+2.7% YoY
Revenue Growth
+0.0%
EPS Growth
-76.9%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | 0 | 0 |
| Gross Profit | 0 | 0 |
| Operating Income | -2M | -2M |
| EBITDA | -2M | -2M |
| Net Income | -2M | -2M |
| EPS (Diluted) | — | — |
Balance sheet
USD
| Metric | 2024 | 2023 |
|---|---|---|
| Cash & Equivalents | 873K | 1M |
| Total Assets | 2M | 2M |
| Total Liabilities | 2M | 2M |
| Shareholder Equity | -177K | 86K |
| Total Debt | 121K | 25K |
| Net Debt | -752K | -1M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
1M
-1.2% YoY
Capital Expenditures
44K
+55.5% YoY
Free Cash Flow
1M
+2.7% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-141.7%
Debt / Equity
0.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.